Synthesis of 1-(2-aminophenyl)isoquinolines and the biological activity of their cis-dichloro platinum(II) complexes

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3478-3485

  Von Nussbaum, Franz ^a   Miller, Bernhard ^a   Wild, Stefan ^a   Hilger, Christoph S ^a   Schumann, Susanne ^a   Zorbas, Haralabos ^a   Beck, Wolfgang ^a   Steglich, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (2 AMINO 5 METHOXYPHENYL) 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE]DICHLOROPLATINUM; [1 (2 AMINOPHENYL) 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE]DICHLOROPLATINUM; CISPLATIN; ISOQUINOLINE DERIVATIVE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGENATION; LEUKEMIA CELL; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA REPLICATION; ISOQUINOLINES; LEUKEMIA L1210; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0033539054     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980434t     Document Type: Article

References (43)

1. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumor agents. Nature 1969, 222, 385-386.
2. (a) Reedijk, J. New insights about the interaction of cisplatinum with intracellular components. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Howell, S. B., Ed.; Plenum Press: New York, 1991; pp 13-23.
3. (b) Wang, K.; Lu, J.; Li, R. The events that occur when cisplatin encounters cells. Coord. Chem. Rev. 1996, 151, 53-88.
4. (c) Neidle, S. DNA Structure and Recognition; Oxford University Press: London, 1994.
5. (d) Wickham, G.; Wakelin, L.; Palmer, B.; Lee, H.; Johnson, P.; Baguley, B.; Denny, W.; McFadyen, D. Cis-diammineplatinum(II) complexes tethered to DNA-affinic Ligands: antitumor activity and DNA-binding properties. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Howell, S. B., Ed.; Plenum Press: New York, 1991; pp 51-60.
6. Sherman, S. E.; Lippard, S. J. Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev. 1987, 87, 1153-1181.
7. Hambley, T. W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord. Chem. Reviews 1997, 166, 181-223.
8. (a) Farrell, N.; Kelland, L. R.; Roberts, J. D.; van Beusichem, M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 1992, 52, 5065-5072.
9. (b) van Beusichem, M.; Farrell, N. Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole, and quinoline. Crystal and molecular structure of trans-dichloro(thiazole)platinum(II). Inorg. Chem. 1992, 31, 634-639.
10. Farrell, N.; Tam, T. B.; Souchard, J.-P.; Wimmer, F. L.; Cros, S.; Johnson, N. P. Cytostatic trans-platinum(II) complexes. J. Med. Chem. 1989, 32, 2240-2254.
11. (a) Deacon, G. B. Synthesis and antitumor activity of some novel platinum(II) organoamids and organometallics. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Howell, S. B., Ed.; Plenum Press: New York, 1991; pp 139-150.
12. 2(N-donor)Cl]+. J. Med. Chem. 1989, 32, 128-136.
13. (c) Köckerbauer, R.; Bednarski, P. J. Unusual reactivity of cisplatin analogues that bear o-phenylenediamine ligands: insights for the design of more effective cytotoxic agents. J. Inorg. Biochem. 1996, 62, 281-298.
14. 2 (L = monofunctional thiourea derivative; L-L = bifunctional thiourea derivative). Inorg. Chem. 1998, 37, 708-716.
15. Muggia, F. M. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin. Oncol. 1989, 16, 7-13.
16. (a) Kidani, Y.; Inagaki, K.; Iigo, M.; Hoshi, A.; Kuretani, K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J. Med. Chem. 1978, 21, 1315-1318.
17. (b) Noji, M.; Okamoto, K.; Kidani, Y.; Tashiro, T. Relation of conformation to antitumor activity of platinum-(II) complexes 1,2-cyclohexanediamine and 2-(aminomethyl)-cyclohexylamine isomers against leukemia P388. J. Med. Chem. 1981, 24, 508-515.
18. (a) Rezler, E. M.; Fenton, R. R.; Esdale, W. J.; McKeage, M. J.; Russel, P. J.; Hambley, T. W. Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl-and N,N-dimethyl-(R)-and -(S)-3-aminohexahydroazepinedichloroplatinum(II). J. Med. Chem. 1997, 40, 3508-3515.
19. (b) Fenton, R. R.; Easdale, W. J.; Er, H. M.; O'Mara, S. M.; McKeage, M. J.; Russell, P. J.; Hambley, T. W. Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)-and (S)-3-aminohexahydroazepine]dichloroplatinum(II). J. Med. Chem. 1997, 40, 1090-1098.
20. Sampedro, F.; Ruiz van Haperen, V. W. T.; Izquierdo, M. A.; Vicens, M.; Santaló, P.; Pueyo, M.; Llagostera, M.; Marcuello, E.; De Andrés, L. Preclinal studies with new pyrrolidine platinum(II) compounds. Eur. J. Med. Chem. 1995, 30, 497-501.
21. Inagaki, K.; Tajima, K.; Kidani, Y.; Tashiro, T.; Tsukagoshi, S. Synthesis and antitumor activity of aminomethylpiperidine platinum(II) complexes, Inorg. Chim. Acta 1979, 37, L547-L548.
22. (a) Holford, J.; Raynaud, F.; Murrer, B. A.; Grimaldi, K.; Hartley, J. A.; Abrams, M.; Kelland, J. R. Chemical, biochemical and pharmacological activity of novel sterically hindered platinum coordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II)(AMD473). Anti-Cancer Drug Des. 1998, 13, 1-18.
23. (b) Chen, Y.; Guo, Z; Parsons, S.; Sadler, P. J. Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complex. Chem. Eur. J. 1998, 4, 672-676.
24. Bierbach, U.; Farrell, N. Modulation of nucleotide binding of trans-platinum(II) complexes by planar ligands. A combined proton NMR and molecular mechanics study. Inorg. Chem. 1997, 17, 33657-3665.
25. Farrell, N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Metal Ions Biol. Systems 1996, 32, 603-639.
26. Venkov, A. P.; Lukanov, L. K. New modification of the intramolecular α-amidoalkylation for the synthesis of 2-acyl-1,2,3,4-tetrahydroisoquinolines. Synthesis 1989, 59-61.
27. (a) Hilger, C. S.; Fugmann, B.; Steglich, W. Synthesis of Necatorone. Tetrahedron Lett. 1985, 26, 5975-5978.
28. (b) von Nussbaum, F. Dissertation, Ludwig-Maximilians-Universität München, 1998.
29. Weygand, F.; Frauendorfer, E. Reduktive Entfernung des N-Trifluoracetyi-und N-Trifluoracetylrestes durch Natriumborhydrid mit Anwendungen in der Peptidchemie. Chem. Ber. 1970, 103, 2437-2449.
30. Bellamy, F. D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron. Lett. 1984, 25, 839-842.
31. 4) amides. Inorg. Chem. 1995, 34, 2316-2322.
32. The torsion angle was calculated with RESVIEW Version 2.22 (02.02.1998). Copyright H. Schwenk.
33. (a) Khokhar, A. R.; Shamsuddin; Al-Baker, S.; Shah, C. Synthesis and characterization of new ethylenediamine and 1,1-bis(aminomethyl)cyclohexane-platinum(II) complexes containing disubstituted sulfide as a leaving group. J. Coord. Chem. 1995, 36, 7-12.
34. (b) Fontes, A. P. S.; Zou, Y.; Farrell, N. Synthesis of functionalized platinum complexes containing DMSO as leaving group. Observation of novel steric control of intrastrand versus interstrand cross-linking by use of bulky ligands. J. Inorg. Biochem. 1994, 55, 79-85.
35. Bednarski, P. Reactions of a cisplatin analogue bearing an estrogenic 1,2-diarylethylenediamine ligand with sulfur-containing amino acids and glutathione. J. Inorg. Biochem. 1995, 80, 1-19.
36. Lippert, B.; Beck, W. Platin-Komplexe in der Krebstherapie. Chem. Unserer Zeit 1983, 6, 190-199.
37. Tonew, M.; Tonew, E.; Gutsche, W.; Wohlrabe, K.; Stelzner, A. M.; Schröder, H.-P.; Heyn, B. Über biologische Wirkungen von Koordinationsverbindungen der Übergangsmetalle. Zum Einfluss von DMSO auf die zytotoxischen, antiviralen und antitumoralen Eigenschaften von Cis-chloro-diammin-platin(II): "Cis-Platin". Zbl. Bakt. Hyg. 1984, A 257, 108-120.
38. Wild, S. C. Diplomarbeit, Ludwig-Maximilians-Universität München, 1998.
39. Armarego, W. L. F.; Smith, J. I. C. Quinazolines Part VIII. Electronic effects in 2-substituted quinazolines. J. Chem. Soc. C 1966, 234-239.
40. Bishop, D. C.; Tucker, M. Isoquino[2,1-c]quinazolines: a novel cyclization. J. Chem. Ind. 1969, 417. No analytical data in this article.
41. Huls, R.; Gaspers, J.; Watin, R. Isolement et synthèse d'un alcaloïde dérivé de l'indéno-[1,2,3-ij] isoquinoléine, extrait de Triclisia gilletii (Dewild) Staner. Bull. Soc. Roy. Sci. Liège 1976, 45, 40-45.
42. Rajagopalan, S. Synthetical experiments in the group of sympathomimetics III. Proc. Indian Acad. Sci. 1941, 14A, 126-132; Chem. Abstr. 1942, 36, 16037.
43. Rajagopalan, S. Synthetical experiments in the group of sympathomimetics III. Proc. Indian Acad. Sci. 1941, 14A, 126-132; Chem. Abstr. 1942, 36, 16037.